Rodent models have long been used as one of the most important tools to understand the mechanisms of ischemic stroke. In many preclinical stroke studies, the effect of treatment is assessed by statistically comparing the cerebral infarct size of the treatment group with that of the placebo group. Infarct volume is a direct measurement of one of the final pathologic steps leading to defects caused by ischemic stroke. Several methods exist to measure infarct volume in experimental stroke models. The traditional method of using postmortem histologic examination to study the extent of neuronal death (infarction) is still considered the gold standard. In addition, there are a range of different calculations/estimates used to determine infarct area and volume.
Fig. 1. Infarct size was showed by TTC staining of brain sections. (Nematipour et al., 2020)
Ace Therapeutics provides reliable infarct volume measurement services to quantify cerebral infarct size in animal models of stroke. We quantitate infarct volume non-invasively using histologically stained brain sections (e.g. hematoxylin and eosin, cresyl violet or 2,3,4-triphenyl tetrazolium chloride (TTC)) or using T2-weighted MRI. Our team of highly skilled experts ensures precise and reliable measurements, providing our clients with accurate data for their studies.
In both transient and permanent focal ischemia models, infarct volume is typically analyzed after 12-24 h. The following is a specific protocol for calculating cerebral infarct volume through TTC staining:
Our infarct volume measurement outcomes provide an objective, quantitative assessment of brain damage and serve as an experimental endpoint or measurement in studies using stroke animals.
Why Choose Us
Ace Therapeutics provides reproducible and low-cost methods to measure infarct volume in animal models of stroke. The results have been widely used as a metric to evaluate stroke models and evaluate potential therapeutics. If you are interested in our services, please do not hesitate to contact us!
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.